DICLOFENAC SOLUTION

Χώρα: Καναδάς

Γλώσσα: Αγγλικά

Πηγή: Health Canada

Δραστική ουσία:

DICLOFENAC SODIUM

Διαθέσιμο από:

PHARMA STULLN INC.

Φαρμακολογική κατηγορία (ATC):

S01BC03

INN (Διεθνής Όνομα):

DICLOFENAC

Δοσολογία:

0.1%

Φαρμακοτεχνική μορφή:

SOLUTION

Σύνθεση:

DICLOFENAC SODIUM 0.1%

Οδός χορήγησης:

OPHTHALMIC

Μονάδες σε πακέτο:

0.3MLX10 X20 X50

Τρόπος διάθεσης:

Prescription

Θεραπευτική περιοχή:

ANTIALLERGIC AGENTS

Περίληψη προϊόντος:

Active ingredient group (AIG) number: 0114417004; AHFS:

Καθεστώς αδειοδότησης:

APPROVED

Ημερομηνία της άδειας:

2018-06-19

Αρχείο Π.Χ.Π.

_Diclofenac Sodium Ophthalmic Solution _
_Page 1 of 26 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
DICLOFENAC
Diclofenac Sodium Ophthalmic Solution
Ophthalmic solution, 0.1% w/v for Topical use
Anti-inflammatory agents, non-steroids
Pharma Stulln Inc
6500 Transcanada Highway, Suite 400
Pointe-Claire
Quebec
H9R0A5
Date of Initial Authorization:
JUN 19, 2018
Date of Revision:
November 16, 2023
Submission Control Number: 275190
_Diclofenac Sodium Ophthalmic Solution _
_ _
_Page 3 of 26 _
RECENT MAJOR LABEL CHANGES
7 WARNINGS AND PRECAUTIONS, Reproductive Health:
Female and Male Potential
11/2023
7 WARNINGS AND PRECAUTIONS, 7.1.1 Pregnant
Women
11/2023
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
TABLE OF CONTENTS
RECENT MAJOR LABEL CHANGES
............................................................................................................................................
3
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................................................................................
5
1
INDICATIONS
..................................................................................................................................................................
5
1.1
P
EDIATRICS
.......................................................................................................................................................................
5
1.2
G
ERIATRICS
.......................................................................................................................................................................
5
2
CONTRAINDICATIONS
.....................................................................................................................................................
5
4
DOSAGE AND ADMINISTRATION
....................................................................................................................................
5
4.2
R
ECOMMENDED
D
OSE AND
D
OSAGE
A
DJUSTM